India / 200% Pharma Sector Budget Boost; 3x Industry Growth in Next Decade; Pfizer Vaccine Rebuffed
The latest news from Indian pharma, including a 200 percent boost for the country’s pharmaceutical industry in…
Address: Claris Corporate HeadquartersNr. Parimal Crossing, Ellisbridge,Ahmedabad – 380 006,India.,India
Tel: -26563319
Web: http://www.clarislifesciences.com/
Claris Lifesciences is one of the largest sterile injectables pharmaceutical companies in India with a market presence in 76 countries worldwide. We primarily manufacture and market products across multiple markets, and therapeutic segments. A significant majority of these products are generic drugs that are capable of being directly injected into the human body and are predominantly used in the treatment of critical illnesses.
Our customer base primarily includes government and private hospitals, aid agencies, and nursing homes.
We have five manufacturing facilities spread over a 78-acre campus located in Ahmedabad,India. Certain of these facilities have been approved by foreign regulatory authorities including the USFDA, MHRA (UK), TGA (Australia), NAM (Finland), GCC FDCA (Gulf Co-operation Council including Saudi Arabia, U.A.E. and other countries in the Middle East), ANVISA (Brazil) and INVIMA (Colombia). Our manufacturing capabilities have received several awards from prestigious institutions like IDMA (Indian Drug Manufacturers’ Association) and Frost & Sullivan.
Our capabilities and experience span across all business verticals in the generic injectables industry. We have a trained workforce across business functions, such as R&D for product development, regulatory affairs for obtaining product registrations, manufacturing, and sales and marketing.
Our products range across various therapeutic segments, including anaesthesia, critical care, anti-infectives, renal care, infusion therapy, enteral & parenteral nutrition and oncology. We offer injectables in various delivery systems, such as glass and plastic bottles, vials, ampoules, pre-filled syringes and non-PVC/PVC bags.
The latest news from Indian pharma, including a 200 percent boost for the country’s pharmaceutical industry in…
The USD 41 billion Indian pharma industry, the world’s third largest by volume and 13th largest by value, stands…
Six Indian pharma and biotech firms have joined the global race to develop a vaccine for COVID-19 with…
COVID-19 restrictions have severely hampered multinational pharma companies who rely on India for generics and…
A recent IQVIA report highlights the increasing importance of Indian firms to the USA’s burgeoning generic…
The ongoing coronavirus outbreak and the subsequent shutdown of factories in China is having severe repercussions…
Below is a selection of the top stories in Indian pharma from recent months, ranging from efforts to counter the…
Biocon, the first Indian company to have a biosimilar drug approved in the US, is taking another step forward with…
The state of Gujarat proudly stands as India’s main pharmaceutical hub, accounting for over 33 percent of the…
Unlike many of his pharma peers, Vivek Sharma worked in operations and finance for two decades before joining the…
The pharmaceutical industries of China and India, historically focused on their large domestic markets and exports…
Aditya Bhattacharji is Healthcare Practice Head at Eurasia Group. In this article, he looks at India’s…